India-based pharmaceutical company Jubilant Pharmova Limited announced on Friday that its subsidiary Jubilant HollisterStier LLC (JHS), a North American pharmaceutical contract manufacturer that specialises in sterile injectables, has successfully launched its new sterile fill & finish line, the third at its Spokane Manufacturing Facility in Washington, USA.

The launch was marked by the successful production of the inaugural batch, initiating revenue generation from the new line. This milestone is claimed to represent a significant advancement in Jubilant HollisterStier's multi-phase expansion strategy and brings an additional 50% capacity at the Spokane facility.

JHS's new production line features advanced isolator technology designed to deliver enhanced sterility assurance, throughput and operational precision. Built to global regulatory standards, it enhances the company's ability to support complex injectable programmes across a broad range of therapeutic areas. The USD132m investment towards this new third line, together with the commissioning of its upcoming fourth line, means that JHS is on track to double its total sterile injectable manufacturing capacity at its Spokane facility.